StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $0.63 | $0.63 | -0.27% | 0.0M |
| 05-12 | $0.59 | $0.63 | +5.88% | 0.0M |
| 05-13 | $0.60 | $0.58 | -3.03% | 0.1M |
| 05-14 | $0.57 | $0.55 | -3.51% | 0.1M |
| 05-15 | $0.57 | $0.54 | -4.98% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.
No sell-side coverage available for IBO.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $7.00K | $32.00K | $25.00K | $7.00K |
Operating Income | $-2.29M | $-4.28M | $-3.11M | $-2.17M |
Net Income | $-2.29M | $-11.84M |
| $-17.08M |
| $-15.61M |
EPS (Diluted) | $-0.02 | $-0.38 | $-1.41 | $-1.29 |
Total Assets | $17.09M | $17.41M | $18.21M | $19.06M |
Total Liabilities | $2.38M | $1.85M | $27.06M | $26.44M |
Cash & Equivalents | $20.00K | $3.00K | $12.00K | $624.00K |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 107.82M | 104.62M | 12.19M | 12.19M |